Welcome to LookChem.com Sign In|Join Free
  • or
Naphthalene, 1-bromo-3-fluoro-, also known as 1-bromo-3-fluoronaphthalene, is an organic compound with the chemical formula C10H6BrF. It is a halogenated derivative of naphthalene, a polycyclic aromatic hydrocarbon consisting of two fused benzene rings. The molecule features a bromine atom at the 1-position and a fluorine atom at the 3-position, which are both substituents on the naphthalene core. Naphthalene, 1-bromo-3-fluoro- is of interest in chemical research and synthesis due to its unique electronic properties and potential applications in the development of new materials and pharmaceuticals. It is typically synthesized through electrophilic substitution reactions and can be used as a building block for more complex organic molecules.

343-53-3

Post Buying Request

343-53-3 Suppliers

Recommended suppliers

  • Product
  • FOB Price
  • Min.Order
  • Supply Ability
  • Supplier
  • Contact Supplier

343-53-3 Usage

Check Digit Verification of cas no

The CAS Registry Mumber 343-53-3 includes 6 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 3 digits, 3,4 and 3 respectively; the second part has 2 digits, 5 and 3 respectively.
Calculate Digit Verification of CAS Registry Number 343-53:
(5*3)+(4*4)+(3*3)+(2*5)+(1*3)=53
53 % 10 = 3
So 343-53-3 is a valid CAS Registry Number.

343-53-3Relevant academic research and scientific papers

Fragment-Based Discovery of MRTX1719, a Synthetic Lethal Inhibitor of the PRMT5?MTA Complex for the Treatment of MTAP-Deleted Cancers

Aranda, Ruth,Bobinski, Thomas P.,Briere, David M.,Burns, Aaron C.,Christensen, James G.,Clarine, Jeffery,Engstrom, Lars D.,Gunn, Robin J.,Ivetac, Anthony,Jean-Baptiste, Ronald,Ketcham, John M.,Kobayashi, Masakazu,Kuehler, Jon,Kulyk, Svitlana,Lawson, J. David,Marx, Matthew A.,Moya, Krystal,Olson, Peter,Rahbaek, Lisa,Smith, Christopher R.,Thomas, Nicole C.,Wang, Xiaolun,Waters, Laura M.

supporting information, p. 1749 - 1766 (2022/02/05)

The PRMT5?MTA complex has recently emerged as a new synthetically lethal drug target for the treatment of MTAP-deleted cancers. Here, we report the discovery of development candidate MRTX1719. MRTX1719 is a potent and selective binder to the PRMT5?MTA complex and selectively inhibits PRMT5 activity in MTAP-deleted cells compared to MTAP-wild-type cells. Daily oral administration of MRTX1719 to tumor xenograft-bearing mice demonstrated dose-dependent inhibition of PRMT5-dependent symmetric dimethylarginine protein modification in MTAP-deleted tumors that correlated with antitumor activity. A 4-(aminomethyl)phthalazin-1(2H)-one hit was identified through a fragment-based screen, followed by X-ray crystallography, to confirm binding to the PRMT5?MTA complex. Fragment growth supported by structural insights from X-ray crystallography coupled with optimization of pharmacokinetic properties aided the discovery of development candidate MRTX1719.

KRAS G12D INHIBITORS

-

Paragraph 0943, (2021/03/05)

The present invention relates to compounds that inhibit KRas G12D. In particular, the present invention relates to compounds that inhibit the activity of KRas G12D, pharmaceutical compositions comprising the compounds and methods of use therefor.

MTA-Cooperative PRMT5 Inhibitors

-

Paragraph 0436, (2021/03/19)

The present invention relates to compounds that inhibit Protein Arginine N-Methyl Transferase 5 (PRMT5) activity. In particular, the present invention relates to compounds, pharmaceutical compositions and methods of use, such as methods of treating cancer using the compounds and pharmaceutical compositions of the present invention.

Post a RFQ

Enter 15 to 2000 letters.Word count: 0 letters

Attach files(File Format: Jpeg, Jpg, Gif, Png, PDF, PPT, Zip, Rar,Word or Excel Maximum File Size: 3MB)

1 Customer Service

What can I do for you?
Get Best Price

Get Best Price for 343-53-3